Protein kinase inhibitors of the quinazoline class exert anti-cytomegaloviral activity in vitro and in vivo
Cytomegalovirus infection is associated with severe disease in immunocompromised individuals. Current antiviral therapy faces several limitations. In a search of novel drug candidates, we describe here the anti-cytomegaloviral properties of two compounds of the chemical class of quinazolines, gefiti...
Gespeichert in:
Veröffentlicht in: | Antiviral research 2008-07, Vol.79 (1), p.49-61 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Cytomegalovirus infection is associated with severe disease in immunocompromised individuals. Current antiviral therapy faces several limitations. In a search of novel drug candidates, we describe here the anti-cytomegaloviral properties of two compounds of the chemical class of quinazolines, gefitinib (Iressa
®) and Ax7396 (RGB-315389). Both compounds showed strong inhibitory effects
in vitro against human and animal cytomegaloviruses with IC
50s in a low micromolar range. Cytotoxicity did not occur at these effective concentrations. The antiviral mode of action was based on the inhibition of protein kinase activity, mainly directed to a viral target kinase (UL97/M97) in addition to cellular target candidates. This was demonstrated by a high sensitivity of the respective protein kinases
in vitro and by infection experiments with viral mutants carrying genomic alterations in the ORF UL97/M97 modulating viral drug sensitivity. In a guinea pig model, gefitinib showed inhibition of cytomegaloviral loads in blood and lung tissue. Importantly, the rate of mortality of infected animals was reduced by gefitinib treatment. In contrast to the
in vitro data, Ax7396 showed no significant antiviral activity in a mouse model. Further
in vivo analyses have to assess the potential use of gefitinib in the treatment of cytomegalovirus disease. |
---|---|
ISSN: | 0166-3542 1872-9096 |
DOI: | 10.1016/j.antiviral.2008.01.154 |